Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GeNeuro Australia PTY Ltd
With
Southern Star Research
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects diagnosed with type 1 diabetes in the 4 years prior to signed informed consent;
Peak stimulated C-peptide of ≥0.2 nmol/L during a mixed meal tolerance test performed during the Screening period;
18 to 55 years of age (both inclusive);
Body weight \>40 to ≤100 kg;
Subjects positive for at least one diabetes-associated autoantibody (insulin, glutaminic-acid-decarboxylase-65 \[GAD-65\], tyrosine phosphatase-related antigen 2 \[IA-2\], ZnT8 or islet-cell antibody \[ICA\]).
You may not be if
Subjects with type 2 diabetes;
Pregnant and nursing women.
Clareo Health | Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years
